Optimized Antibody Therapy for Acute Blood Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 240
Special Issue Editors
Interests: stem cell transplantation; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In 1997 rituximab was approved as the first therapeutic antibody for human malignancy. We now have a great number of monoclonal antibodies at our disposal. The diseases and indications for antibody therapy are growing rapidly, and have extended from leukemias and lymphomas to antibody-mediated autoimmune diseases, non-malignant hematology and hemostaseology.
Indispensable for the effect of a therapeutic antibody is not only a wise choice of antigen or target, but also the nature of the Fc fragment—whether it is humanized and which IgG subclass it consists of. The antibodies display their activity by antibody-dependent cytotoxicity or complement activation. Some antibodies have been coupled to a drugs to induce direct cytotoxicity. Bi- or trispecific antibodies have been introduced, simultaneously engaging tumor cells and autologous immune cells or binding more than one antigen on a target cell. Recently, checkpoint inhibitors have been used against a variety of tumors, inducing a non-specific immune stimulation. Current clinical trials are investigating the combination of such checkpoint inhibitors with tumor-specific monoclonal antibodies.
Many questions remain unanswered, such as the optimal time point to introduce antibody therapy or mechanisms to enhance their activity or obtain synergistic effects.
Prof. Dr. Rupert Handgretinger
Dr. Manon Queudeville
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- therapeutic antibodies
- hematological diseases
- immunotherapy
